Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK2334470是一种高效的、特异性的PDK1抑制剂,IC50=10 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 198 | 现货 | ||
5 mg | ¥ 461 | 现货 | ||
10 mg | ¥ 742 | 现货 | ||
25 mg | ¥ 1,380 | 现货 | ||
50 mg | ¥ 2,480 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 817 | 现货 |
产品描述 | GSK2334470 is a novel PDK1 inhibitor (IC50: ~10 nM, in a cell-free assay), with no inhibitory at other close related AGC-kinases. |
靶点活性 | PDK1:10 nM |
体内活性 | The efficacy of the PDK1 inhibitor (PDKi) GSK2334470 is tested in newborn BrafV600E::Pten?/?mice subjected to systemic administration of 4-HT. Twice weekly administration of PDK1 results in marked inhibition of pigmented lesions and concomitant melanomagenesis, as well as significant inhibition of lung metastases, seen by H&E staining-based quantification (~80%), and lymph node metastases as by S100 immunostaining, similar to the phenotype seen upon genetic ablation of Pdk1[4]. |
激酶实验 | FGFR1-4 Biochemical Assays: FGFR kinase inhibition assays are performed at KM for ATP. Picomolar to low nanomolar concentrations of FGFR proteins are incubated in 1× Kinase Reaction Buffer (KRB) with 1 μM of CSKtide and 50 to 250 of μM ATP at 25°C for 90 minutes in the presence or absence of a dosed concentration series of inhibitor. All reactions are terminated by the addition of Stop buffer, and plates are read on a Caliper EZReader2. IC50 values are fit with a four-parameter log[Inhibitor] versus response model with floating Hill Slope. |
细胞实验 | GSK2334470 is dissolved in DMSO and diluted with appropriate medium before use. To study the inhibitory effect of GSK2334470 on mTOR-S6K pathway, non-resistant cells and the resistant sublines are treated with GSK2334470 at 5 μM for 1.5 and 12 h in 10 % FBS medium with/without MK-2206 (5 μM)[2]. |
分子量 | 462.59 |
分子式 | C25H34N8O |
CAS No. | 1227911-45-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 83 mg/mL (179.4 mM)
DMSO: 83 mg/mL (179.4 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.1617 mL | 10.8087 mL | 21.6174 mL | 54.0435 mL |
5 mM | 0.4323 mL | 2.1617 mL | 4.3235 mL | 10.8087 mL | |
10 mM | 0.2162 mL | 1.0809 mL | 2.1617 mL | 5.4044 mL | |
20 mM | 0.1081 mL | 0.5404 mL | 1.0809 mL | 2.7022 mL | |
50 mM | 0.0432 mL | 0.2162 mL | 0.4323 mL | 1.0809 mL | |
100 mM | 0.0216 mL | 0.1081 mL | 0.2162 mL | 0.5404 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GSK2334470 1227911-45-6 PI3K/Akt/mTOR signaling PDK GSK-2334470 Inhibitor GSK 2334470 PDK-1 inhibit inhibitor